Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Peritoneal Neoplasms 1Colorectal Neoplasms 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 49Cyclophosphamide 34Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × LY-2157299 × Gynecologic × Clear all
NCT05700656 2024-07-22

Galunisertib Combined With Capecitabine in Advanced CRC With PM

The Netherlands Cancer Institute

Phase 1/2 Recruiting
31 enrolled
GastrointestinalGynecologic

Peritoneal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡